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Background: Misdiagnosis of malaria by commercial rapid diagnostic tests (RDTs) is a major cause of concern in
the diagnosis of malaria. This retrospective study was aimed at assessing the relative performance of four RDTs
with emphasis on the detection of two Plasmodium vivax antigens: aldolase and lactate dehydrogenase (LDH).
Methods: Three commercially available Plasmodium LDH or aldolase antigen detection kits (One Step Malaria P.f/P.v,
ParaHit Total ver. 1.0, SD Bioline Malaria) and an anti-P. vivax aldolase-specific monoclonal antibody (mAb) pair 1C3-12 F10
were evaluated with P. vivax positive as well as non-P. vivax samples and healthy samples using blood smear examination
as standard. Each test was read according to the manufacturer’s instructions.
Results: MAb 1C3-12 F10 pair targeting P. vivax-specific aldolase exhibited very good specificity and sensitivity of 100 and
97.4%, respectively. Positive predictive value (PPV) and negative predictive value (NPV) of 100 and 99.5%, respectively,
were also observed. The anti-P. vivax LDH in the One-Step Malaria P.f/P.v test showed sensitivity, specificity, PPV and NPV
of 93.5, 98.0, 88.9 and 98.8%, respectively. ParaHit Total ver. 1.0 targeting the pan-aldolase antigen showed sensitivity,
specificity of 97.4 and 99.6%, respectively. PPV and NPV were both 99.5%. SD Bioline had sensitivity, specificity, PPV and
NPV of 93.5, 100, 100 and 98.8%, respectively. The overall sensitivity and specificity of all four RDTs were acceptable,
especially for the aldolase detection tests. Five (6.5%) of the P. vivax-positive samples (n = 77) that were confirmed by
microscopic examination as well as the two aldolase detection RDTs (mAb 1C3-12 F10 and ParaHit Total ver.1.0) were
undetected by the two LDH detection RDTs (One Step Malaria P.f/P.v and SD Bioline). Similarly, two positive samples
(2.6%) that were positively confirmed by the LDH detection RDTs were also undetected by the aldolase detection test kits.
Conclusion: Aldolase and LDH antigens perform differently in different P. vivax samples; hence there is a high risk of
misdiagnosis when monoclonal antibodies are used against only one particular antigen in the test. A combination of
both aldolase and LDH in RDTs for the rapid diagnosis of P. vivax will enhance the sensitivity of the assay and reduce
misdiagnosis.
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Malaria is a deadly infectious disease with a global im-
pact extending from the most developed countries to
the most remote regions of the world [1]. Worldwide
malaria mortality rates have been significantly reduced
over the last decade by 45% in all age groups and by
51% in children under five years of age [2]. This is a* Correspondence: jufwang@scut.edu.cn
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unless otherwise stated.significant success and highlights progress towards the
global malaria targets of reducing the incidence rate by
75% by 2015 [3]. However, there is no need for compla-
cency but rather a more focused approach to ensure that
misdiagnosis which results in treatment delays [4] and
subsequent mortality does not occur in future.
The standard method of malaria diagnosis is by the
routine microscopic examination of Giemsa-stained blood
smears [5]. Fluorescent staining methods such as quantita-
tive buffy coat (QBC) have also been recommended for useLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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assays for easy and inexpensive diagnosis of malaria in-
fection has been effective in areas where expertise in
microscopic diagnosis is unavailable [7]. Rapid diag-
nostic tests (RDTs) that detect malaria parasite pro-
teins by immunochromatography have been used as
complementary detection method for malaria diagnosis
[8,9]. These tests are convenient and simple to operate
and facilitate the rapid testing of clinical specimens
within 10 to 30 minutes [10]. RDTs for malaria offer
the greatest possibility of extending accurate malaria
diagnosis to remote areas where trained personnel,
microscopes and other equipment are not easily ac-
cessible [11]. Malaria RDTs have been developed with
great focus on the detection of histidine-rich protein 2
(PfHRP2) from Plasmodium falciparum and parasite-
specific lactate dehydrogenase (pLDH) or Plasmodium
aldolase (pALDO) from all species [7]. The PfHRP2-
based test is a reliable complimentary test to routine
microscopy for the diagnosis of P. falciparum malaria
[12], however, the relative sensitivity and specificity of
RDTs to non-P. falciparum species is low [11-13].
Recent advances in the development of species-specific
RDTs, such as the Plasmodium vivax aldolase-specific test
[14], will greatly enhance the quality of testing and reduce
over-administration of anti-malarial drugs in endemic areas
to a more species-specific approach to the treatment of
malaria.
In this research, the comparative study of the diag-
nostic performance of four rapid malaria RDTs (One
Step Malaria P.f/P.v, ParaHit Total ver. 1.0, SD Bioline
Malaria and monoclonal antibody (mAb) pair 1C3-
12 F10) is reported. The 1C3-12 F10 mAb pair was se-
lected from a number of anti-aldolase mAb secreting
clones, developed to specifically detect only the
P. vivax aldolase antigen as reported earlier [14]. One
Step Malaria P.f/P.v (Guangzhou Wondfo Biotech Co
Ltd, China) contains an anti-LDH mAb pair that is
specific to P. vivax LDH antigen, and SD Bioline
Malaria (Standard Diagnostics, Korea) detects the pan-
LDH antigen, while the ParaHit Total ver.1.0 (Span
Diagnostics Ltd, India) detects the pan-aldolase anti-
gen. The relative performance of these RDTs was com-
pared for their ability to detect the P. vivax parasite in
clinical samples.Table 1 Detailed information on Plasmodium vivax rapid diag
Test assay Manufacturer/source P. vivax
mAb 1C3-12 F10 Developed by Dzakah et al. [14] P. vivax aldo
One Step Malaria P.f/P.v Guangzhou Wondfo Biotech, China Pan-LD
ParaHit Total ver. 1.0 Span Diagnostics Ltd, India Pan -aldola
SD BIOLINE Malaria Standard Diagnostics, Korea Pan-LDMethods
Sample collection
Venous blood sample taken in an anticoagulant (EDTA)-
containing tube was used for thick and thin blood
smears. Sample tubes were stored at −20°C until needed
for laboratory examination. Thick and thin blood smears
were prepared and read as described earlier by the
WHO standard method [15]. Each slide was independently
examined by two experienced microscopists at the Yunnan
Provincial Institute of Parasitic Diseases, who were blinded
to the patients’ characteristics and symptoms. Plasmodium
vivax-positive blood samples (n = 77) and non-P. vivax
samples (n = 33) were collected from patients in the
Yunnan Province of China. Non-P. vivax samples included
P. falciparum (n = 31) and P. malariae (n = 2) samples.
Healthy blood samples (n = 423) were randomly collected
from volunteers in Guangzhou. These volunteers had no
recent history or symptoms of malaria infection and were
diagnosed as having no Plasmodium species in the blood.
Diagnosis with rapid diagnostic tests
Three commercially available Plasmodium LDH or al-
dolase antigen detection kits (One Step Malaria P.f/P.v,
ParaHit Total ver. 1.0, SD Bioline Malaria) and an anti-
P. vivax aldolase mAb pair 1C3-12 F10 were used
(Table 1). The test was conducted using anti-coagulated
venous blood. Each test was performed and read within
a specific time interval according to the manufacturer’s
instructions. Test was recorded as positive if both the
test (T) band corresponding to either LDH or aldolase,
and control (C) band appeared; if only the C line was
seen, it was recorded as negative according to the manu-
facturer’s instruction. Each test was observed by two ex-
perienced technicians who were blinded to the results of
one another. Band intensity at the end of the stipulated
reaction time was compared to a standard colour chart
with colour range between C1 (deepest) to C8 (faintest).
Negative samples were designated as C9.
Data analysis
The sensitivity and specificity of the immunochromato-
graphic assay for the detection of P. vivax were com-
pared with thick blood microscopic examination results
by Kappa statistical analysis, K. P < 0.005 was considered
as significant.nostic tests evaluated in this study
antigen Specimen Format Time Method of analysis
lase (PvALDO) Whole blood Cassette 15 min Eye
H (pLDH) Whole blood Cassette 15 min Eye
se (pALDO) Whole blood Cassette 25 min Eye
H (pLDH) Whole blood Cassette 20 min Eye
Table 3 Band intensity of different target antigen rapid













2 12 17 46 77
One step
malaria P.f/P.v
5 9 14 49 77
ParaHit total
ver. 1.0
2 11 18 46 77
SD bioline
malaria
5 7 15 50 77
Band intensities were recorded independently by two individuals who were
blinded to the observation of each other.
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Three commercial RDTs and an antibody pair developed
earlier were investigated in this study. The various RDTs
were retrospectively studied for their ability to detect
either the aldolase or LDH antigen in clinical samples.
All five P. vivax-positive samples which showed false
negative results in the two LDH-detecting categories
were detected with very strong bands in the aldolase-
detecting category. Similarly, the two positive samples
that were not detected in the aldolase category were
however strongly detected in the LDH category (Table 2).
Samples showing no bands were graded C9 for respect-
ive test kit (Table 3).
MAb 1C3-12 F10 pair exhibited excellent specificity
and sensitivity of 100% (95% Confidence interval (CI):
99.1-100.0%) and 97.4% (95% CI: 90.9-99.6%), respect-
ively (Table 4). The sensitivity and specificity observed
by the One-Step Malaria P.f/P.v test were 93.5% (95% CI:
85.5-97.8%) and 97.9% (95% CI: 96.0-99.0%), respectively.
Sensitivity and specificity of ParaHit Total ver. 1.0 were
97.4% (95% CI: 90.9-99.6%) and 99.5% (95% CI: 98.3-
99.9%), respectively. SD Bioline had similar sensitivity
(93.5%) as observed in One-Step Malaria P.f/Pv but an ex-
cellent specificity of 100% (95% CI: 99.1-100.0%). All non-P.
vivax samples were negative in the 1C3-12 F10 mAb pair
combination, OneStep Malaria P.f/P.v and ParaHit Total
ver 1.0 test kits as expected since the antigens used in these
assays either target the P. vivax specific LDH and aldolase
or pan-specific aldolase. These were however positive in
the SD Bioline assay as the detection antigen was pan-
LDH. The general performance of these tests kits were
good compared with the microscopy gold standard obser-
vation (Table 4).
Discussion
The significance of the use of RDTs in reducing malaria
mortality and prevalence cannot be over-emphasized.
Nonetheless, misdiagnosis of malaria contributes largelyTable 2 Comparison of four malaria rapid diagnostic tests
with microscopic examination




+(%) -(%) +(%) -(%)
mAb 1C3-12 F10 75 (97.4) 2 (2.6) 0 (0) 456 (100)
One Step Malaria P.f/P.v 72 (93.5) 5 (6.5) 9 (2.0) 447 (98.0)
ParaHit Total ver. 1.0 75 (97.4) 2 (2.6) 2 (0.4) 454 (99.6)
SD Bioline Malaria 72 (93.5) 5 (6.5) 0 (0) 423 (100)
Plasmodium vivax-negative samples refer to both non-P. vivax specimen as
well as specimen collected from healthy individuals with no history of malaria
infection. In the case of SD Bioline, P. vivax negative samples included only
healthy samples.
“+ and -” represent the number of detected and undetected
specimen, respectively.to the over-prescription of anti-malarial drugs such as
artemisinin leading to the rise in drug resistance globally
[16], with its consequent delay or incomplete clearance
of parasites from the patient’s blood [4,16]. Plasmodium
resistance has been documented in three of the five
malaria species known to infect humans: P. falciparum,
P. vivax and Plasmodium malariae. Thus, improving the
accuracy of malaria diagnosis is becoming more pivotal
and must be treated with all the seriousness it deserves
in the future.
The present study investigated the performance of mal-
aria RDTs targeting either the P. vivax-specific aldolase or
LDH antigens or the pan-specific forms compared to the
standard microscopic blood smear examination. The anti-
aldolase mAb pair 1C3-12 F10 and the anti-LDH mAbs
used in the One-Step Malaria P.f/P.v specifically detect
only the P. vivax while the mAb pairs used in the ParaHit
Total ver. 1.0 and SD Bioline are pan-specific aldolase and
LDH, respectively, as indicated in Table 1. The tests were
performed according to the manufacturer’s instruction
and then read at the stipulated time.
Previous studies on the SD Bioline RDT reported sen-
sitivity ranges between 92.7 and 98.8% [17,18] when fro-
zen and fresh samples from South Korea were used. In
this study, there was an observed sensitivity of 93.5%
and an excellent specificity of 100%. The difference inTable 4 Sensitivity, specificity, positive predictive value,
negative predictive value and Kappa comparison of the











1C3-12 F10 97.4 100 100 99.5 0.9844
One-step
malaria
93.5 98.0 88.9 98.8 0.8958
ParaHit total 97.4 99.6 99.5 99.5 0.9697
SD bioline 93.5 100 100 98.8 0.9609
PPV, Positive predictive value; NPV, Negative predictive value.
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ent samples evaluated and the regions from which they
were collected. Earlier study on anti-P. vivax aldolase
antibodies reported a sensitivity of 98.3% and specificity
of 99.2% [14]. The anti-P. vivax aldolase mAb pair used
in this research estimates improved specificity of 100%
for P. vivax and a slightly reduced sensitivity 97.4%.
One-Step Malaria P.f/P.v, which uses anti-P. vivax-spe-
cific LDH mAb showed sensitivity and specificity of
93.5% and 98.0%, respectively. The pan-specific aldolase
antigen ParaHit Total ver. 1.0 test showed sensitivity of
97.4% and specificity of 99.6% (Table 4). All four RDTs
employed in this study showed good agreement with the
microscopic smear examination.
While the specificity of the different RDTs varies in
the detection of P. vivax, one most important finding in
this study is the similarity in the percentage sensitivities
observed by the different categories of RDTs from differ-
ent manufacturers but targeting a particular antigen of
interest. MAb pair 1C3-12 F10 and ParaHit Total ver.1.0
target the aldolase antigen, although the 1C3-12 F10
mAb pair is P. vivax-specific while the ParaHit Total
ver. 1.0 is pan-specific in nature. Both tests estimated an
overall sensitivity of 97.4%, much higher than the 93.5%
observed for the LDH target in the One-Step Malaria
P.f/Pv (P. vivax-specific LDH) and the SD Bioline (pan-
LDH). An interesting observation made in this study
was the fact that the two undetected samples in the al-
dolase category (1C3-12 F10 and ParaHit Total ver. 1.0)
were all detected with very strong bands by the LDH
category (One-Step Malaria P.f/P.v and SD Bioline).
Similarly, all the five undetected P. vivax samples in the
LDH category were all detected with strong bands by
the aldolase category (Table 3). From this result, it is
infered that the use of aldolase as a target antigen for
the detection of P. vivax in clinical samples may provide
more reliable diagnosis of the parasite. However, because
both aldolase and LDH performed differently in different
samples, there is the risk of misdiagnosis when mono-
clonal antibodies are used against only one particular
antigen in the test. A combination of both aldolase and
LDH in RDTs for the diagnosis of P. vivax will greatly
improve the sensitivity of the assay.
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